IL-15 enhances the antitumor effect of human antigen-specific CD8+ T cells by cellular senescence delay

OncoImmunology

Volumn 5, Issue 12, 2016, Pages

  Weng, Jinsheng ^a,b   Moriarty, Kelsey E ^a   Baio, Flavio Egidio ^a   Chu, Fuliang ^a   Kim, Sung Doo ^a   He, Jin ^a   Jie, Zuliang ^a   Xie, Xiaoping ^a   Ma, Wencai ^a   Qian, Jianfei ^a   Zhang, Liang ^a   Yang, Jing ^a   Yi, Qing ^a   Neelapu, Sattva S ^a   Kwak, Larry W ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Idiotype; IL 15; immunotherapy; myeloma; senescence; T cells

Indexed keywords

CD27 ANTIGEN; CD28 ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 2A; GAMMA INTERFERON; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 8; IONOMYCIN; JANUS KINASE 3; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN P53; SHORT HAIRPIN RNA; STAT5 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL CYCLE ASSAY; CELL EXPANSION; CELLULAR IMMUNITY; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DNA DAMAGE; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOSENESCENCE; MOUSE; MYELOMA; NONHUMAN; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; U266 CELL LINE; WESTERN BLOTTING;

EID: 84996868148     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1237327     Document Type: Article

References (73)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA:A Cancer Journal for Clinicians 2016; 66(1):7-30; PMID:26742998; http://dx.doi.org/10.3322/caac.21332
2. June CH. Adoptive T cell therapy for cancer in the clinic. J Clin Investig 2007; 117(6):1466-76; PMID:17549249; http://dx.doi.org/10.1172/JCI32446
3. June CH. Principles of adoptive T cell cancer therapy. J Clin Investig 2007; 117(5):1204-12; PMID:17476350; http://dx.doi.org/10.1172/JCI31446
4. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer:a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008; 8(4):299-308; PMID:18354418; http://dx.doi.org/10.1038/nrc2355
5. Dudley ME, Rosenberg SA. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 2003; 3(9):666-75; PMID:12951585; http://dx.doi.org/10.1038/nrc1167
6. Schluns KS, Lefrancois L. Cytokine control of memory T-cell development and survival. Nat Rev Immunol 2003; 3(4):269-79; PMID:12669018; http://dx.doi.org/10.1038/nri1052
7. Badovinac VP, Tvinnereim AR, Harty JT. Regulation of antigen-specific CD8+ T cell homeostasis by perforin and interferon-γ. Science 2000; 290(5495):1354-7; PMID:11082062; http://dx.doi.org/10.1126/science.290.5495.1354
8. Refaeli Y, Van Parijs L, London CA, Tschopp J, Abbas AK. Biochemical mechanisms of IL-2–regulated fas-mediated T cell apoptosis. Immunity 1998; 8(5):615-23; PMID:9620682; http://dx.doi.org/10.1016/S1074-7613(00)80566-X
9. Lodolce JP, Boone DL, Chai S, Swain RE, Dassopoulos T, Trettin S, Ma A. IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity 1998; 9(5):669-76; PMID:9846488; http://dx.doi.org/10.1016/S1074-7613(00)80664-0
10. Rathmell JC, Farkash EA, Gao W, Thompson CB. IL-7 enhances the survival and maintains the size of naive T cells. J Immunol 2001; 167(12):6869-76; PMID:11739504; http://dx.doi.org/10.4049/jimmunol.167.12.6869
11. Tan JT, Dudl E, LeRoy E, Murray R, Sprent J, Weinberg KI, Surh CD. IL-7 is critical for homeostatic proliferation and survival of naïve T cells. Proc Natl Acad Sci 2001; 98(15):8732-7; PMID:11447288; http://dx.doi.org/10.1073/pnas.161126098
12. Spolski R, Leonard WJ. Interleukin-21:a double-edged sword with therapeutic potential. Nat Rev Drug Discov 2014; 13(5):379-95; PMID:24751819; http://dx.doi.org/10.1038/nrd4296
13. Cousens LP, Orange JS, Biron CA. Endogenous IL-2 contributes to T cell expansion and IFN-gamma production during lymphocytic choriomeningitis virus infection. J Immunol 1995; 155(12):5690-9; PMID:7499855
14. Khoruts A, Mondino A, Pape KA, Reiner SL, Jenkins MK. A natural immunological adjuvant enhances T cell clonal expansion through a CD28-dependent, interleukin (IL)-2-independent mechanism. J Exp Med 1998; 187(2):225-36; PMID:9432980; http://dx.doi.org/10.1084/jem.187.2.225
15. Li XC, Demirci G, Ferrari-Lacraz S, Groves C, Coyle A, Malek TR, Strom TB. IL-15 and IL-2:a matter of life and death for T cells in vivo. Nat Med 2001; 7(1):114-8; PMID:11135625; http://dx.doi.org/10.1038/83253
16. Klebanoff CA, Finkelstein SE, Surman DR, Lichtman MK, Gattinoni L, Theoret MR, Grewal N, Spiess PJ, Antony PA, Palmer DC, et al. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc Natl Acad Sci U S A 2004; 101(7):1969-74; PMID:14762166; http://dx.doi.org/10.1073/pnas.0307298101
17. Weng J, Cha SC, Matsueda S, Alatrash G, Popescu MS, Yi Q, Molldrem JJ, Wang M, Neelapu SS, Kwak LW. Targeting human B-cell malignancies through Ig light chain-specific cytotoxic T lymphocytes. Clin Cancer Res 2011; 17(18):5945-52; PMID:21813633; http://dx.doi.org/10.1158/1078-0432.CCR-11-0970
18. Weng J, Neelapu SS, Woo AF, Kwak LW. Identification of human idiotype-specific T cells in lymphoma and myeloma. Curr Top Microbiol Immunol 2011; 344:193-210; PMID:20549471; http://dx.doi.org/10.1007/82_2010_70
19. Weng J, Rawal S, Chu F, Park HJ, Sharma R, Delgado DA, Fayad L, Fanale M, Romaguera J, Luong A, et al. TCL1:a shared tumor-associated antigen for immunotherapy against B-cell lymphomas. Blood 2012; 120(8):1613-23; PMID:22645177; http://dx.doi.org/10.1182/blood-2011-09-382838
20. Topalian SL, Muul LM, Solomon D, Rosenberg SA. Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. J Immunol Methods 1987; 102(1):127-41; PMID:3305708; http://dx.doi.org/10.1016/S0022-1759(87)80018-2
21. Riddell SR, Greenberg PD. The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. J Immunol Methods 1990; 128(2):189-201; PMID:1691237; http://dx.doi.org/10.1016/0022-1759(90)90210-M
22. Miyakawa Y, Ohnishi Y, Tomisawa M, Monnai M, Kohmura K, Ueyama Y, Ito M, Ikeda Y, Kizaki M, Nakamura M. Establishment of a new model of human multiple myeloma using NOD/SCID/gammac(null) (NOG) mice. Biochem Biophys Res Commun 2004; 313(2):258-62; PMID:14684154; http://dx.doi.org/10.1016/j.bbrc.2003.11.120
23. Mirandola L, Yu Y, Chui K, Jenkins MR, Cobos E, John CM, Chiriva-Internati M. Galectin-3C inhibits tumor growth and increases the anticancer activity of bortezomib in a murine model of human multiple myeloma. PLoS One 2011; 6(7):e21811; PMID:21765917; http://dx.doi.org/10.1371/journal.pone.0021811
24. Passos JF, Simillion C, Hallinan J, Wipat A, von Zglinicki T. Cellular senescence:unravelling complexity. Age 2009; 31(4):353-63; PMID:19618294; http://dx.doi.org/10.1007/s11357-009-9108-1
25. Campisi J. senescent cells, tumor suppression, and organismal aging:good citizens, bad neighbors. Cell 2005; 120(4):513-22; PMID:15734683; http://dx.doi.org/10.1016/j.cell.2005.02.003
26. Ye J, Huang X, Hsueh EC, Zhang Q, Ma C, Zhang Y, Varvares MA, Hoft DF, Peng G. Human regulatory T cells induce T-lymphocyte senescence. Blood 2012; 120(10):2021-31; PMID:22723548; http://dx.doi.org/10.1182/blood-2012-03-416040
27. Ben-Porath I, Weinberg RA. The signals and pathways activating cellular senescence. Int J Biochem Cell Biol 2005; 37(5):961-76; PMID:15743671; http://dx.doi.org/10.1016/j.biocel.2004.10.013
28. Zhang H. Molecular signaling and genetic pathways of senescence:Its role in tumorigenesis and aging. J Cell Physiol 2007; 210(3):567-74; PMID:17133363; http://dx.doi.org/10.1002/jcp.20919
29. Fridman AL, Tainsky MA. Critical pathways in cellular senescence and immortalization revealed by gene expression profiling. Oncogene 2008; 27(46):5975-87; PMID:18711403; http://dx.doi.org/10.1038/onc.2008.213
30. Akbar AN, Henson SM. Are senescence and exhaustion intertwined or unrelated processes that compromise immunity? Nat Rev Immunol 11(4):289-95; PMID:21436838; http://dx.doi.org/10.1038/nri2959
31. Montes CL, Chapoval AI, Nelson J, Orhue V, Zhang X, Schulze DH, Strome SE, Gastman BR. Tumor-induced senescent T cells with suppressor function:A potential form of tumor immune evasion. Cancer Research 2008; 68(3):870-9; PMID:18245489; http://dx.doi.org/10.1158/0008-5472.CAN-07-2282
32. Pipkin ME, Sacks JA, Cruz-Guilloty F, Lichtenheld MG, Bevan MJ, Rao A. Interleukin-2 and inflammation induce distinct transcriptional programs that promote the differentiation of effector cytolytic T cells. Immunity 2010; 32(1):79-90; PMID:20096607; http://dx.doi.org/10.1016/j.immuni.2009.11.012
33. Malamut G, El Machhour R, Montcuquet N, Martin-Lannerée S, Dusanter-Fourt I, Verkarre V, Mention JJ, Rahmi G, Kiyono H, Butz EA, et al. IL-15 triggers an antiapoptotic pathway in human intraepithelial lymphocytes that is a potential new target in celiac disease–associated inflammation and lymphomagenesis. J Clin Investig 120(6):2131-43; PMID:20440074; http://dx.doi.org/10.1172/JCI41344
34. Cornish GH, Sinclair LV, Cantrell DA. Differential regulation of T-cell growth by IL-2 and IL-15. Blood 2006; 108(2):600-8; PMID:16569767; http://dx.doi.org/10.1182/blood-2005-12-4827
35. Gattinoni L, Powell DJ, Rosenberg SA, Restifo NP. Adoptive immunotherapy for cancer:building on success. Nat Rev Immunol 2006; 6(5):383-93; PMID:16622476; http://dx.doi.org/10.1038/nri1842
36. Besser MJ, Shapira-Frommer R, Treves AJ, Zippel D, Itzhaki O, Hershkovitz L, Levy D, Kubi A, Hovav E, Chermoshniuk N, et al. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin Cancer Res 2010; 16(9):2646-55; PMID:20406835; http://dx.doi.org/10.1158/1078-0432.CCR-10-0041
37. Schmitt TM, Ragnarsson GB, Greenberg PD. T cell receptor gene therapy for cancer. Hum Gene Ther 2009; 20(11):1240-8; PMID:19702439; http://dx.doi.org/10.1089/hum.2009.146
38. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298(5594):850-4; PMID:12242449; http://dx.doi.org/10.1126/science.1076514
39. Hardy NM, Fellowes V, Rose JJ, Odom J, Pittaluga S, Steinberg SM, Blacklock-Schuver B, Avila DN, Memon S, Kurlander RJ, et al. Costimulated tumor-infiltrating lymphocytes are a feasible and safe alternative donor cell therapy for relapse after allogeneic stem cell transplantation. Blood 2012; 119(12):2956-9; PMID:22289893; http://dx.doi.org/10.1182/blood-2011-09-378398
40. Liddy N, Bossi G, Adams KJ, Lissina A, Mahon TM, Hassan NJ, Gavarret J, Bianchi FC, Pumphrey NJ, Ladell K, et al. Monoclonal TCR-redirected tumor cell killing. Nat Med 2012; 18(6):980-7; PMID:22561687; http://dx.doi.org/10.1038/nm.2764
41. Cantrell D, Smith K. The interleukin-2 T-cell system:a new cell growth model. Science 1984; 224(4655):1312-6; PMID:6427923; http://dx.doi.org/10.1126/science.6427923
42. Gillis S, Smith KA. Long term culture of tumour-specific cytotoxic T cells. Nature 1977; 268(5616):154-6; PMID:145543; http://dx.doi.org/10.1038/268154a0
43. Morgan D, Ruscetti F, Gallo R. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 1976; 193(4257):1007-8; PMID:181845; http://dx.doi.org/10.1126/science.181845
44. Crompton JG, Sukumar M, Restifo NP. Uncoupling T-cell expansion from effector differentiation in cell-based immunotherapy. Immunological Rev 2014; 257(1):264-76; PMID:24329803; http://dx.doi.org/10.1111/imr.12135
45. Crespo J, Sun H, Welling TH, Tian Z, Zou W. T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment. Curr Opin Immunol 2013; 25(2):214-21; PMID:23298609; http://dx.doi.org/10.1016/j.coi.2012.12.003
46. Di Mitri D, Azevedo RI, Henson SM, Libri V, Riddell NE, Macaulay R, Kipling D, Soares MV, Battistini L, Akbar AN. Reversible senescence in human CD4+CD45RA+CD27- memory T cells. J Immunol 187(5):2093-100; PMID:21788446; http://dx.doi.org/10.4049/jimmunol.1100978
47. Warrington KJ, Vallejo AN, Weyand CM, Goronzy JrJ. CD28 loss in senescent CD4+ T cells:reversal by interleukin-12 stimulation. Blood 2003; 101(9):3543-9; PMID:12506015; http://dx.doi.org/10.1182/blood-2002-08-2574
48. Herbig U, Jobling WA, Chen BP, Chen DJ, Sedivy JM. Telomere shortening triggers senescence of human cells through a pathway involving ATM, p53, and p21(CIP1), but not p16(INK4a). Mol Cell 2004; 14(4):501-13; PMID:15149599; http://dx.doi.org/10.1016/S1097-2765(04)00256-4
49. Fagagna FdAd, Reaper PM, Clay-Farrace L, Fiegler H, Carr P, von Zglinicki T, Saretzki G, Carter NP, Jackson SP. A DNA damage checkpoint response in telomere-initiated senescence. Nature 2003; 426(6963):194-8; PMID:14608368; http://dx.doi.org/10.1038/nature02118
50. Adams PD. Healing and hurting:molecular mechanisms, functions, and pathologies of cellular senescence. Mol Cell 2009; 36(1):2-14; PMID:19818705; http://dx.doi.org/10.1016/j.molcel.2009.09.021
51. Chen WH, Kozlovsky BF, Effros RB, Grubeck-Loebenstein B, Edelman R, Sztein MB. Vaccination in the elderly:an immunological perspective. Trends Immunol 2009; 30(7):351-9; PMID:19540808; http://dx.doi.org/10.1016/j.it.2009.05.002
52. Campisi J, d'Adda di Fagagna F. Cellular senescence:when bad things happen to good cells. Nat Rev Mol Cell Biol 2007; 8(9):729-40; PMID:17667954; http://dx.doi.org/10.1038/nrm2233
53. Lleonart ME, Artero-Castro A, Kondoh H. Senescence induction; a possible cancer therapy. Mol Cancer 2009; 8:3; PMID:19133111; http://dx.doi.org/10.1186/1476-4598-8-3
54. Acosta JC, O'Loghlen A, Banito A, Guijarro MV, Augert A, Raguz S, Fumagalli M, Da Costa M, Brown C, Popov N, et al. Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell 2008; 133(6):1006-18; PMID:18555777; http://dx.doi.org/10.1016/j.cell.2008.03.038
55. Kuilman T, Michaloglou C, Vredeveld LCW, Douma S, van Doorn R, Desmet CJ, et al. Oncogene-Induced Senescence Relayed by an Interleukin-Dependent Inflammatory Network. Cell 2008; 133(6):1019-31; PMID:18555778; http://dx.doi.org/10.1016/j.cell.2008.03.039
56. Kassem M, Ankersen L, Eriksen EF, Clark BF, Rattan SI. Demonstration of cellular aging and senescence in serially passaged long-term cultures of human trabecular osteoblasts. Osteoporos Int 1997; 7(6):514-24; PMID:9604046; http://dx.doi.org/10.1007/BF02652556
57. d'Adda di Fagagna F. Living on a break:cellular senescence as a DNA-damage response. Nat Rev Cancer 2008; 8(7):512-22; PMID:18574463; http://dx.doi.org/10.1038/nrc2440
58. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, Medrano EE, Linskens M, Rubelj I, Pereira-Smith O. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci 1995; 92(20):9363-7; PMID:7568133; http://dx.doi.org/10.1073/pnas.92.20.9363
59. Jackson JG, Pant V, Li Q, Chang LL, Quintas-Cardama A, Garza D, Tavana O, Yang P, Manshouri T, Li Y, et al. p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer. Cancer Cell 2012; 21(6):793-806; PMID:22698404; http://dx.doi.org/10.1016/j.ccr.2012.04.027
60. Rodier F, Coppe J-P, Patil CK, Hoeijmakers WAM, Munoz DP, Raza SR, Freund A, Campeau E, Davalos AR, Campisi J. Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat Cell Biol 2009; 11(8):973-9; PMID:19597488; http://dx.doi.org/10.1038/ncb1909
61. Appay V, Nixon DF, Donahoe SM, Gillespie GM, Dong T, King A, Ogg GS, Spiegel HM, Conlon C, Spina CA, et al. HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function. J Exp Med 2000; 192(1):63-75; PMID:10880527; http://dx.doi.org/10.1084/jem.192.1.63
62. Vallejo AN. CD28 extinction in human T cells:altered functions and the program of T-cell senescence. Immunol Rev 2005; 205:158-69; PMID:15882352; http://dx.doi.org/10.1111/j.0105-2896.2005.00256.x
63. Darnell JE. STATs and Gene Regulation. Science 1997; 277(5332):1630-5; PMID:9287210; http://dx.doi.org/10.1126/science.277.5332.1630
64. Shuai K, Liu B. Regulation of JAK-STAT signalling in the immune system. Nat Rev Immunol 2003; 3(11):900-11; PMID:14668806; http://dx.doi.org/10.1038/nri1226
65. Costa-Pereira AP, Tininini S, Strobl B, Alonzi T, Schlaak JF, Is'harc H, Gesualdo I, Newman SJ, Kerr IM, Poli V. Mutational switch of an IL-6 response to an interferon-γ-like response. Proc Natl Acad Sci 2002; 99(12):8043-7; PMID:12060750; http://dx.doi.org/10.1073/pnas.122236099
66. Avalle L, Pensa S, Regis G, Novelli F, Poli V. STAT1 and STAT3 in tumorigenesis:A matter of balance. JAKSTAT 2012; 1(2):65-72; PMID:24058752; http://dx.doi.org/10.4161/jkst.20045
67. Cohen PA, Koski GK, Czerniecki BJ, Bunting KD, Fu X-Y, Wang Z, Zhang WJ, Carter CS, Awad M, Distel CA, et al. STAT3- and STAT5-dependent pathways competitively regulate the pan-differentiation of CD34pos cells into tumor-competent dendritic cells. Blood 2008; 112(5):1832-43; PMID:18577706; http://dx.doi.org/10.1182/blood-2007-12-130138
68. Yang X-P, Ghoreschi K, Steward-Tharp SM, Rodriguez-Canales J, Zhu J, Grainger JR, Hirahara K, Sun HW, Wei L, Vahedi G, et al. Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5. Nat Immunol 2011; 12(3):247-54; PMID:21278738; http://dx.doi.org/10.1038/ni.1995
69. d'Adda di Fagagna F, Reaper PM, Clay-Farrace L, Fiegler H, Carr P, Von Zglinicki T, Saretzki G, Carter NP, Jackson SP. A DNA damage checkpoint response in telomere-initiated senescence. Nature 2003; 426(6963):194-8; PMID:14608368; http://dx.doi.org/10.1038/nature02118
70. Grange M, Buferne M, Verdeil G, Leserman L, Schmitt-Verhulst AM, Auphan-Anezin N. Activated STAT5 promotes long-lived cytotoxic CD8+ T cells that induce regression of autochthonous melanoma. Cancer Res 2012; 72(1):76-87; PMID:22065720; http://dx.doi.org/10.1158/0008-5472.CAN-11-2187
71. Kujawski M, Zhang C, Herrmann A, Reckamp K, Scuto A, Jensen M, Deng J, Forman S, Figlin R, Yu H. Targeting STAT3 in Adoptively Transferred T Cells Promotes Their In Vivo Expansion and Antitumor Effects. Cancer Res 2010; 70(23):9599-610; PMID:21118964; http://dx.doi.org/10.1158/0008-5472.CAN-10-1293
72. Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, Pilon-Thomas S, Niu G, Kay H, Mulé J, Kerr WG, et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 2005; 11(12):1314-21; PMID:16288283; http://dx.doi.org/10.1038/nm1325
73. Yang H, Yamazaki T, Pietrocola F, Zhou H, Zitvogel L, Ma Y, Kroemer G. Improvement of immunogenic chemotherapy by STAT3 inhibition. OncoImmunology 2016; 5(2):e1078061; PMID:27057456; http://dx.doi.org/10.1080/2162402X.2015.1078061